Journal article
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial
Abstract
Background/Patients and methods: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins. Perifosine was administered orally in cycles for 21 days out of 28. Loading doses were given day 1 each cycle (900 mg cycle 1, 300 mg cycle 2+) …
Authors
Knowling M; Blackstein M; Tozer R; Bramwell V; Dancey J; Dore N; Matthews S; Eisenhauer E
Journal
Investigational New Drugs, Vol. 24, No. 5, pp. 435–439
Publisher
Springer Nature
Publication Date
September 2006
DOI
10.1007/s10637-006-6406-7
ISSN
0167-6997